Working Groups

Chairman, members

Projects, active/ upcoming protocols

October 2007

Paraclinical

Staging/

Epidemiology

Mats Jerkeman, Lund

Peter Brown, Copenhagen

Stein Kvaløy, Oslo

Tuula Lehtinen, Tampere

·          Clinical staging guidelines 1997

·          Registration: Nordic lymphoma registry

Pathology

Christer Sundström, Uppsala

Elisabeth Ralfkiær, Copenh.

Jan Delabie, Oslo

Marja-Liisa Karjalainen-Lindsberg, Helsinki

·          Pathology-guidelines 1999 (see homepage)

Clinical

Large B-cell lymphoma

Sirpa Leppä, Helsinki

Öystein Fluge, Bergen

Mikael Eriksson, Lund

Magnus Björkholm, St.holm

Anne Bukh, Ålborg

Lars Møller Pedersen, Herlev

Harald Holte, Oslo

Sirkku Jyrkkiö, Turku

·          CHOEP-14+Rituximab with CNS prophylaxis in younger patients with DLBCL/FL gr III with risk factors (NLG-LBC-04; CRY 04)

CNS lymphoma

Elisa Pulczynski, Århus

Martin Erlanson, Umeå

Unn Merethe Fagerli,Trondheim

Outi Kuittinen, Oulu

·          Immunochemotherapy in PCNSL

Hodgkin’s Lymphoma

Gunilla Enblad, Uppsala

Lena Specht, Copenhagen

T.Turpenniemi-Hujanen, Oulu

Alexander Fosså, Oslo

·          Treatment of early-stage Hodgkin

·          Intergroup: (Stage III-IV Hodgkin: BEACOPP vs ABVD (with EORTC)

Mantle cell lymphoma

Chr. Geisler, Copenhagen

Erkki Elonen, Helsinki

Anna Laurell, Uppsala

Arne Kolstad, Oslo

·          MCL-2 protocol activated 2001: Rituximab In vivo purging pre- and  maintenance post-ASCT.

·          MCL-3
 

Intergroup: MCL in the elderly: R-CHOP vs R-FC

Indolent

(Low-grade) lymphomas

Eva Kimby, Huddinge

Mads Hansen, Copenhagen

Tuula Lehtinen, Tampere

Bjørn Østenstad, Oslo

·          New phase III protocol activated 2002:  Rituximab +/- Interferon

Peripheral T-cell NHL:

Francesco D’Amore, Århus

Thomas Relander, Lund

Grete Lauritzen, Oslo

Esa Jantunen, Kuopio

Autologous transplant as primary treatment of peripheral T-cell NHL. Activated 2002; closed 071101.
ACT-1 and ACT-2: CHOP-14 +/- alemtuzumab as primary treatment in PTCL (collab. with the German High-grade non-Hodgkin's lymphoma study group), activated fall 2007.